Stock Watch: Alnylam’s Date With The Competition

In what was one of the most anticipated clinical trial readouts of the year, Alnylam Pharmaceuticals Inc.. announced the results of its 360-patient Phase III APOLLO-B study of Onpattro (patisiran) in transthyretin-mediated (AATR) amyloidosis with cardiomyopathy. Onpattro is already approved in the smaller polyneuropathy AATR amyloidosis population and met APOLLO-B’s six-minute walk distance (6MWD) primary endpoint after 12 months. (Also see "Alnylam Ready To Expand TTR Franchise With Positive Cardiomyopathy Results" - Scrip, 4 August, 2022.)